rct
    2016

    Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis

    Elia AE, Lalli S, Monsurro MR

    Published in European Journal of Neurology

    Methodology

    Randomized double-blind placebo-controlled phase II trial of TUDCA 1 g twice daily added to riluzole for 54 weeks in ALS

    Key Findings

    A greater proportion of TUDCA-treated patients were responders and ALSFRS-R decline was slower than placebo

    Conclusions

    TUDCA was safe and slowed functional decline in this phase II ALS trial

    Limitations

    Phase II, small sample, single primary outcome definition

    Supplements Studied

    TUDCA
    Compound

    TUDCA-treated patients showed slower ALSFRS-R decline than placebo over 54 weeks

    Outcomes Measured

    Neuroprotection

    TUDCA-treated ALS patients showed slower functional decline than placebo

    Study Details

    Year:2016
    Sample Size:34
    Duration:54 weeks
    Quality Score:6/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.